← All trials
NCT05889728
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 20, 2023
- Primary completion
- Feb 20, 2025
- Completion date
- Feb 23, 2025
- First posted
- Jun 5, 2023
- Last posted
- Jun 5, 2023
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of New South WalesLead sponsor
- University of New South WalesOverall official - principal investigator
- University of New South WalesReponsible party - principal investigator
- University of New South WalesOfficial
- NovartisCollaborator
- University of New South WalesSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.